Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Lymphoma or Chronic Lymphocytic Leukemia
NCT02733042Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- May 2016
- Primary completion
- Mar 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 7
01
Overview
Phase 2, open-label trial of durvalumab in lymphoma and chronic lymphocytic leukemia (CLL) (4 arms), sponsored by Celgene Corporation. Primary endpoints: Dose Limiting Toxicities and Treatment-emergent Adverse Events. Started May 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02733042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733042.